Literature DB >> 30578763

UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma.

Xiangjun Qiu1, Saili Xie2, Lei Ye3, Ren-Ai Xu4.   

Abstract

In the present study, an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) approach was designed to concurrently measure the levels of ertugliflozin and sitagliptin in rat plasma with diazepam as the internal standard (IS). Acetonitrile-based protein precipitation was applied for sample preparation, then analytes (ertugliflozin and sitagliptin) were subjected to gradient elution chromatography with a mobile phase composed of acetonitrile (A) and 0.1% formic acid in water (B). Ertugliflozin was monitored by m/z 437.2 → 329.0 transition for quantification and m/z 437.2 → 207.5 transition for qualification, and sitagliptin was determined by m/z 408.2 → 235.0 transition for quantification and m/z 408.2 → 174.0 transition for qualification by multiple reaction monitoring (MRM) in positive ion electrospray ionization (ESI) source. When the concentration of ertugliflozin ranged from 1 to 1000 ng/mL and sitagliptin ranged from 2 to 2500 ng/mL, the method exhibited good linearity. For both ertugliflozin and sitagliptin, the intra- and inter-day precision were determined with the values of 1.6-10.9% and 0.8-13.3%, respectively; and the accuracy ranged from -5.7% to 14.6%. Matrix effect, extraction recovery, and stability data were in line with the stipulated FDA guidelines for validating a bioanalytical method. The validity of the designed method was confirmed through the pharmacokinetic experiments.
© 2018 Published by Elsevier Inc.

Entities:  

Keywords:  Ertugliflozin; Pharmacokinetics; Rat plasma; Sitagliptin; UPLC-MS/MS

Mesh:

Substances:

Year:  2018        PMID: 30578763     DOI: 10.1016/j.ab.2018.12.016

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  1 in total

1.  UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma.

Authors:  Qingqing Li; Ya-Nan Liu; Jing Wang; Yingying Hu; Jinyu Hu; Ren-Ai Xu; Liu Shao; Lianguo Chen
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.